Cellectis (CLLS) EBITDA (2015 - 2026)

Cellectis' EBITDA history runs 12 years deep, the most recent figure standing at -$25.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 77.49% year-over-year to -$25.2 million; the TTM figure through Mar 2026 stood at -$44.1 million (up 16.61% YoY), while the FY2025 annual figure was -$59.6 million, changed 0.0% from the prior year.
• EBITDA for Q1 2026 stood at -$25.2 million, down from -$17.4 million in the prior quarter.
• The five-year high for EBITDA was $8.0 million in Q3 2025, with the low at -$29.6 million in Q4 2023.
• The 5-year median for EBITDA is -$20.7 million (2023), against an average of -$17.9 million.
• The sharpest annual moves came in 2023 and 2025: EBITDA tumbled 422.6% in 2023, then jumped 174.67% in 2025.
• Cellectis' EBITDA stood at -$5.7 million in 2022, then sank by 422.6% to -$29.6 million in 2023, then surged by 63.89% to -$10.7 million in 2024, then plunged by 62.47% to -$17.4 million in 2025, then slumped by 45.04% to -$25.2 million in 2026.
• Business Quant data shows CLLS's EBITDA at -$25.2 million in Q1 2026, -$17.4 million in Q4 2025, and $8.0 million in Q3 2025.